A new design of trial for hypnotics comparison: A double-blind cross-over trial with patient's preference assessment and continuation of the preferred treatment

Bourin, Michel; Malinge, M.

doi:10.1016/0278-5846(96)00003-6

Cited by 4 publications

(1 citation statement)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The objective of this pragmatic trial was not to demonstrate the effectiveness and safety of a drug-which had already been proven in several previous trialsbut to support the general practitioner in taking the best therapeutic decision in his daily practice (Eschwège and Bouvenot, 1994). Several studies have previously applied this method as the main criterion of evaluation for the hypnotics (Danjou et al, 1987;Bourin and Malinge, 1996) or as an evaluative measure of the health-related quality of life (Bliven et al, 1998;Ward et al, 2000). Patrick and Chiang (2000) have analysed the validity of preference-based measures in treatment effectiveness evaluations.…”

Section: Discussionmentioning

confidence: 99%

Preference of insomniac patients between a single dose of zolpidem 10 mg versus zaleplon 10 mg

Allain

Bentué-Ferrer

Breton³

et al. 2003

Human Psychopharmacology

View full text Add to dashboard Cite

We assessed the preference of insomniac patients between a single dose of 10 mg zolpidem or zaleplon, respectively, administered in random order on two consecutive nights. Fifty-three patients (mean age 52.2 years, 51% females) with a history of recurrent episodes of insomnia and currently complaining of difficulties in falling asleep were included into a randomized, double-blind, cross-over study by 12 general practitioners. After each night, the patients were asked to fill in a sleep questionnaire and visual analogue scales (VAS) to subjectively assess both the quality of sleep (in the morning) and the quality of the day (in the evening). After the second study night, patients' self-assessed preference was established through a drug preference questionnaire. 62% of patients preferred zolpidem, while 38% preferred zaleplon (p = 0.08). The quality of sleep items getting to sleep and quality of sleep were significantly more improved after zolpidem (p = 0.03 and p < 0.0001, respectively). On the VAS, subjective sleep quality was significantly better after zolpidem (p < 0.0001). Diurnal awakeness and quality of day life were satisfying in both groups, without significant difference. The subjective total duration of sleep was 8.0 h for zolpidem and 8.1 h for zaleplon (n.s.). Safety was good and similar between the two drugs. Insomniac patients tended to prefer zolpidem to zaleplon on both nocturnal and diurnal assessments. These results provide additional information for the physician's choice, based on the patient's preference for a given drug.

show abstract

Section: Discussionmentioning

confidence: 99%

Preference of insomniac patients between a single dose of zolpidem 10 mg versus zaleplon 10 mg

Allain

Bentué-Ferrer

Breton³

et al. 2003

Human Psychopharmacology

View full text Add to dashboard Cite

show abstract

Sedative‐Hypnotics

Vida¹,

Yevich

2003

Burger's Medicinal Chemistry and Drug Discovery

View full text Add to dashboard Cite

This chapter focuses on sedative‐hypnotic drugs that are sued to alleviate the condition of sleep disturbances. One‐third of our life is spent in sleep; the lack, of which, can cause serious physical, social, and psychological problems. This chapter describes the features of an ideal hypnotic drug and provides a classification of sedative‐hypnotic drugs currently in use. These include the barbiturates, benzodiazepines, halogenated sedative‐hypnotics, heterocyclic sedative‐hypnotics, antihistamines, and other sedative‐hypnotics. Individual members of all of these classes of drugs are discussed in detail. The chapter also describes the physiology of sleep and the sleep cycle, including the nonrapid eye movement and rapid eye movement sleep. A list of neurotransmitters and nonhypnotic drugs that have a direct and indirect action on the sleep cycle are provided. The pharmacology including the evaluation of sedative‐hypnotics are also given. The chapter refers to the discovery of one of the most frequently prescribed hypnotic drugs, Zolpidem. The chapter also examines structure‐activity relationships, recent developments, things to come, and available websites.

show abstract

Treating Insomnia: A Review of Patient Perceptions Toward Treatment

Cheung

Bartlett

Armour

et al. 2015

Behavioral Sleep Medicine

View full text Add to dashboard Cite

Patient views about their treatment for insomnia often dictate outcome. This review explores the literature relating to the patients' global perceptions toward treatment for insomnia. A strategic literature search was conducted using five databases (PubMed, CINAHL, Medline, PsycINFO, and Embase). The 57 research articles included for this review were mapped out chronologically across three key stages of treatment-seeking (pretreatment appraisal, actual treatment experiences, and posttreatment evaluation). Patient perceptions played an important role across these three key stages and influenced subsequent health behaviors such as the initiation of help-seeking, treatment uptake, treatment adherence, and treatment adjustment. Patients' perceptions toward treatment were heavily grounded by their psychosocial contexts. Clinical implications and future directions for including patient-centered metrics in mainstream practice and research are discussed.

show abstract

A new design of trial for hypnotics comparison: A double-blind cross-over trial with patient's preference assessment and continuation of the preferred treatment

Cited by 4 publications

References 8 publications

Preference of insomniac patients between a single dose of zolpidem 10 mg versus zaleplon 10 mg

Preference of insomniac patients between a single dose of zolpidem 10 mg versus zaleplon 10 mg

Sedative‐Hypnotics

Treating Insomnia: A Review of Patient Perceptions Toward Treatment

Contact Info

Product

Resources

About